| __timestamp | MannKind Corporation | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79383000 | 49315000 |
| Thursday, January 1, 2015 | 108402000 | 75043000 |
| Friday, January 1, 2016 | 46928000 | 83749000 |
| Sunday, January 1, 2017 | 74959000 | 122682000 |
| Monday, January 1, 2018 | 79716000 | 207761000 |
| Tuesday, January 1, 2019 | 74669000 | 284812000 |
| Wednesday, January 1, 2020 | 59040000 | 317875000 |
| Friday, January 1, 2021 | 77417000 | 282660000 |
| Saturday, January 1, 2022 | 91473000 | 451421000 |
| Sunday, January 1, 2023 | 94314000 | 481871000 |
Cracking the code
In the competitive world of biotechnology, managing operational costs is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Sarepta Therapeutics, Inc. and MannKind Corporation from 2014 to 2023. Over this period, Sarepta's SG&A expenses surged by nearly 900%, reflecting its aggressive expansion and investment in research and development. In contrast, MannKind's expenses remained relatively stable, with a modest increase of about 19%. This disparity highlights different strategic approaches: while Sarepta focuses on scaling and innovation, MannKind maintains a steady operational model. Notably, in 2023, Sarepta's SG&A expenses were approximately five times higher than MannKind's, underscoring its commitment to growth. These trends offer valuable insights into how biotech firms allocate resources to sustain competitive advantage and drive future success.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MannKind Corporation
Pfizer Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
Vertex Pharmaceuticals Incorporated vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Genmab A/S or Sarepta Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Viatris Inc. and MannKind Corporation
Dr. Reddy's Laboratories Limited and MannKind Corporation: SG&A Spending Patterns Compared
Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Pharming Group N.V.
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.
Sarepta Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Sarepta Therapeutics, Inc. vs Veracyte, Inc.: SG&A Expense Trends
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation